Outlook Therapeutics regains Nasdaq compliance after bid-price cure
Outlook Therapeutics received notice on June 26, 2026 that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after the closing bid price of its common stock remained at $1.00 or greater for ten consecutive business days between June 11–25, 2026. The company had been notified on February 18, 2026 of a delisting determination for failing to maintain the minimum bid price for 30 consecutive business days, but the delisting matter is now closed.
Key facts
- Closing bid price $1.00 or greater for ten consecutive business days between June 11–25, 2026
- Original delisting notice February 18, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days
- Nasdaq Listing Rule 5550(a)(2)
- Matter closed as of June 26, 2026
Why it matters
Outlook has cured the bid-price deficiency and avoided delisting from the Nasdaq Capital Market, preserving its public exchange listing and market access.
Share
Derived from 8-K filed 2026-06-26. Not investment advice. View the source filing on SEC.gov →